• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INSM alert in real time by email
    New Drug Application (NDA): 207356
    Company: INSMED INC
    • Email
    • Medication Guide

    Products on NDA 207356

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    ARIKAYCE KIT AMIKACIN SULFATE EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 207356

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    09/28/2018 ORIG-1 Approval Type 3 - New Dosage Form PRIORITY Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/207356Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207356Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    02/10/2023 SUPPL-12 Labeling-Medication Guide, Labeling-Package Insert

    Label is not available on this site.

    03/13/2020 SUPPL-4 Labeling-Medication Guide, Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207356s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/207356Orig1s004ltr.pdf
    10/19/2020 SUPPL-3 Efficacy-Labeling Change With Clinical Data Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/207356Orig1s003ltr.pdf

    Labels for NDA 207356

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    03/13/2020 SUPPL-4 Labeling-Medication Guide Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207356s004lbl.pdf
    03/13/2020 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207356s004lbl.pdf
    09/28/2018 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf
    Get the next $INSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INSM

    DatePrice TargetRatingAnalyst
    4/10/2026$200.00Outperform
    Raymond James
    3/30/2026$212.00Equal-Weight → Overweight
    Morgan Stanley
    3/16/2026Buy
    Jefferies
    1/28/2026$231.00Overweight
    Barclays
    1/23/2026$212.00Buy
    Roth Capital
    12/19/2025$202.00Buy
    Truist
    12/4/2025$263.00Buy
    Rothschild & Co Redburn
    10/28/2025$192.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Smith Michael Alexander sold $666,982 worth of shares (6,149 units at $108.47) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 41,613 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    5/22/26 4:25:21 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $2,718,224 worth of shares (25,564 units at $106.33) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 273,037 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    5/20/26 4:06:20 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bonstein Sara sold $961,041 worth of shares (8,272 units at $116.18), decreasing direct ownership by 10% to 71,486 units (SEC Form 4) (withholding obligation)

    4 - INSMED Inc (0001104506) (Issuer)

    5/15/26 4:08:11 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

    BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET.This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30 days following the conclusion of this live event.About InsmedInsmed Incorporated is a people-first global b

    5/27/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

    — Total Company Revenues of $306.0 Million for the First Quarter of 2026——BRINSUPRI® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025—— ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025——Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million—— Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints——Phase 3 PALM-PAH Study of TPIP

    5/7/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

    —New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI® on Respiratory Symptoms——Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprostinil Palmitil Inhalation Powder Phase 3 Development Program——Additionally, Insmed Provides Independent Research Grant to the American Thoracic Society for a Landmark Quality Initiative to Improve Diagnosis of Bronchiectasis across the U.S.—BRIDGEWATER, N.J., May 4, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced th

    5/4/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desjardins Clarissa bought $201,694 worth of shares (3,025 units at $66.68) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    5/22/25 5:20:35 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    SEC Filings

    View All

    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    SEC Form S-3ASR filed by Insmed Incorporated

    S-3ASR - INSMED Inc (0001104506) (Filer)

    5/15/26 5:02:24 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INSMED Inc (0001104506) (Filer)

    5/15/26 4:01:27 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INSMED Inc (0001104506) (Filer)

    5/7/26 7:01:37 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Insmed with a new price target

    Raymond James initiated coverage of Insmed with a rating of Outperform and set a new price target of $200.00

    4/10/26 8:32:03 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Insmed from Equal-Weight to Overweight and set a new price target of $212.00

    3/30/26 8:13:23 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Insmed

    Jefferies resumed coverage of Insmed with a rating of Buy

    3/16/26 9:36:08 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Insmed Incorporated

    SC 13G - INSMED Inc (0001104506) (Subject)

    9/3/24 5:22:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Insmed Incorporated (Amendment)

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    2/16/24 5:43:57 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Financials

    Live finance-specific insights

    View All

    Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

    — Total Company Revenues of $306.0 Million for the First Quarter of 2026——BRINSUPRI® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025—— ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025——Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million—— Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints——Phase 3 PALM-PAH Study of TPIP

    5/7/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026

    BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2026 financial results on Thursday, May 7, 2026.Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss financial results and provide a business update.Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7

    4/23/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

    —The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rates——In the Second Half of 2026, Insmed Plans to File a Supplemental NDA for ARIKAYCE with the FDA and Submit the Data to the PMDA in Japan to Support Potential Label Changes——Insmed to Host Investor Conference Call on Monday, March 23, 2026, at 8:00 AM ET—BRIDGEWATER, N.J., March 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of p

    3/23/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

    —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year

    10/24/24 4:05:00 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Names Drayton Wise Chief Commercial Officer

    BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti

    5/23/22 8:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care